Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
959.41 USD
↗ 43.35 (4.73%)AT CLOSE (03:59 PM EST)
962.59
↗ 3.18 (0.33%)
POST MARKET (AS OF 05:39 PM EST)
Post Market
AS OF 05:39 PM EST
962.59
↗ 3.18 (0.33%)
🟢Market: OPEN

Regeneron Pharmaceuticals Inc (REGN) trades at $962.59 per share. Technical and fundamental signals align bullish — technicals rate "Strong Buy" while fundamentals indicate "Buy". Key drivers include a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. REGN is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 11, 2026.

Open?$904.99
High?$961.98
Low?$898.29
Prev. Close?$916.06
Volume?1.2M
Avg. Volume?853.1K
VWAP?$933.10
Rel. Volume?1.45x
Bid / Ask
Bid?$902.72 × 40
Ask?$1,004.14 × 40
Spread?$101.42
Midpoint?$953.43
Valuation & Ratios
Market Cap?94.8B
Shares Out?101.6M
Float?95.7M
Float %?94.6%
P/E Ratio?19.67
P/B Ratio?2.83
EPS?$46.57
Dividend?0.40%
Ex-Dividend?2026-11-20
News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
94.8B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
100
Momentum?
62
Short Sent.?
84
Piotroski F-Score?6/9Mixed
Altman Z-Score?7.59Safe
Confidence?74%Moderate
Full Fundamental Analysis →
Short InterestLow
Short % of Float?2.32%Low
Short Interest?2.2M
Days to Cover?2.7
Free Float95.7M
Avg Daily Volume810.9K
Settlement Date2026-10-30
Financial Health
Current Ratio?3.35Strong
Quick Ratio?2.89Strong
Cash Ratio?0.59Adequate
Debt/Equity?0.08Low
ValuationFAIRLY VALUEDvs 10 peers + S&P 500
Score
72/100
P/E?
Peers
100
S&P
66
19.7FAIR▾
P/B?
Peers
73
S&P
58
2.83CHEAP▾
P/S?
Peers
82
S&P
25
5.61FAIR▾
P/FCF?
Peers
63
S&P
40
24.8FAIR▾
EV/EBITDA?
Peers
75
S&P
36
17.5FAIR▾
EV/Sales?
Peers
91
S&P
31
5.55FAIR▾
Returns & Efficiency
ROE?
Peers
43
S&P
52
14.4%STRONG▾
ROA?
Peers
71
S&P
77
10.9%STRONG▾
Cash Flow & Enterprise
FCF?$3.8B
Enterprise Value?$93.8B
Fundamentals ratios updated end of day
MarketsMoversWatchlist